/ /

  • linkedin
  • Increase Font
  • Sharebar

    Surgical options for reducing risk in BRCA mutation carriers


    Take-home message

    Proven benefits of RRSO in premenopausal BRCA mutation carriers against both breast and ovarian cancer must be weighed carefully against the sequelae of surgically induced menopause, including risks of cardiovascular disease, osteoporosis, dementia, and impaired quality of life.

    Current models of pelvic serous carcinogenesis suggest that interval salpingectomy is a logical option to reduce cancer risk. The procedure should be discussed with young BRCA mutation carriers, taking into consideration a patient’s individual risks and priorities.39



    1.     Siegel RL, Miler KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin. 2015;65(1):5–29.

    2.     Walsh T, et al. Mutations in 12 genes for inherited ovarian, tubal and peritoneal carcinoma identified by parallel sequencing Pro Natl Acad Sci USA. 2011;108(44):18032–18037.

    3.     Chen S, Parmigianoi G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 2007;25(11):1329–1333.

    4.     Antoniou A, Pharoah PDP, Narid SA, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: a combined analysis of 22 studies. Am J Human Genet. 2003;72(5):1117–1130.

    5.     King MC, Marks JH, Mandell JB. New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science. 2003;302(5645):643–646.

    6.     Domcheck S, Friebel T, Singer CF, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010;304:967–975.

    7.     Finch A, Lubinski J, Moller P, et al. The impact of oophorectomy on cancer incidence and mortality in women with BRCA1 or BRCA2 mutation. J Clin Oncol. 2014;32:1547–1553.

    8.     Rebbeck TR, Kauff ND, Domchek SM. Meta-analysis of risk reduction estimates with risk-reducing salpingo-oophorectomy in BRCA1 or BRCA2 mutation carriers. JNCI. 2009;101(2):80–87.

    9.     Hereditary breast and ovarian cancer syndrome. ACOG Technical Bulletin 103. Obstet Gynecol. 2009;113(4):957–966.

    10.  Leeper K, Garcia R, Swisher E, Greer B, Paley P. Pathologic findings in prophylactic oophorectomy specimens in high-risk women. Gynecol Oncol. 2002;87(1):52–56.

    11.  Powell, CB, Kenley E, Chen LM, et al. Risk-reducing salpingo-oophorectomy in BRCA mutation carriers: role of serial sectioning in the detection of occult malignancy. J Clin Oncol. 2005; 23(1):127–132.

    12.  Finch, A, Beiner M, Lubinski J, et al; Hereditary Ovarian Cancer Clinical Study Group. Salpingo-oophorectomy and the risk of ovarian, Fallopian tube, and peritoneal cancers in women with a BRCA1 or BRCA2 Mutation. JAMA. 2006;296(2):185–192.

    13.  Callahan, MJ, Crum CP, Medeiros F, et al. Primary Fallopian tube malignancies in BRCA-positive women undergoing surgery for ovarian cancer risk reduction. J Clin Oncol. 2007;25: 3985–3990.

    14.  Powell CB, Chen L, McLennan J, et al. Risk-reducing salpingo-oophorectomy(RRSO) in BRCA mutation carriers: experience with consecutive series of 111 patients using a standardized surgical-pathological protocol. Int J Gynecol Cancer. 2011;21(5):846–851.

    15.  Conner JR, Meserve E, Pizer E, et al. Outcome of unexpected adnexal neoplasia discovered during risk reduction salpingo-oophorectomy in women with germ-line BRCA1 or BRCA2 mutations. Gynecol Oncol. 2014;133(2):280–286.

    16.  Crum, CP, Drapkin R, Miron A, et al. The distal Fallopian tube: a new model for pelvic serous carcinogenesis. Curr Opin Obstet Gynecol. 2007;19(1):3–9.

    17.  Kindelberger DW, Lee Y, Miron A, et al. Intraepithelial carcinoma of the fimbria and pelvic serous carcinoma: evidence for a causal relationship. Am J Surg Path. 2007; 31 (2):161–169.

    18.  Medeiros F, Muto M, Lee Y, et al. The tubal fimbria is a preferred site of early adenocarcinoma in women with familial ovarian cancer syndrome. Am J Surg Path. 2006;30(2):230–236.

    19.  Cass I, Walts A, Karlan BY. Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube? Gynecol Oncol. 2010;117(1):27–31.

    20.  Cass I, Holschneider C, Datta N, Barbuto D, Walts AE, Karlan BY. BRCA-mutation-associated Fallopian tube carcinoma. Obstet Gynecol. 2010;106(6):1327–1334.

    21.  Rabban JT, Mackey A, Powell CB, Crawford B, Zaloudek CJ, Chen L. Correlation of macroscopic and microscopic pathology in risk reducing salpingo-oophorectomy: implications for intraoperative specimen evaluation. Gynecol Oncol. 2011;121:466–471.

    22.   Anderson GL, Limacher M, Assaf AR, et al. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the women’s health initiative randomized controlled trial. JAMA. 2004;291:1701–1712.

    23.  Rossouw JE, Anderson GL, Prentice RL, et al. Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled trial. JAMA. 2002;288:321–333.

    24.  Rebbeck TR, Friebel T, Wagner T, et al. Effect of short term hormone replacement therapy on breast cancer risk reduction after bilateral prophylactic oophorectomy in BRCA1 and BRCA2 mutation carriers: the PROSE study group. J Clin Oncol. 2005;23(31):7804–7810.

    25.  Eisen A, Lubinski J, Gronwald J, et al. Hormone therapy and the risk of breast cancer in BRCA mutation carriers. JNCI. 2008;100:1361–1367.

    26.  Rivera CM, Grosshardt BR, Rhodes DJ, et al. Increased cardiovascular mortality after early bilateral oophorectomy. Menopause. 2009;16(1):15–23.

    27.  Segev Y, Iqbal J, Lubinski J, et al. The incidence of endometrial cancer in women with BRCA1 and BRCA2 mutations; an international prospective cohort study. Gynecol Oncol. 2013;130:127–131.

    28.  Lavie O, Ben-Arie A, Segev Y, et al. BRCA germline mutations in women with uterine papillary serous carcinoma-still a debate. Int J Gynecol Cancer. 2010;20:1531–1534.

    29.  Vyarvelska I, Rosen B, Narod SA. Should hysterectomy complement prophylactic salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers? Gynecol Oncol. 2014;134:219–221.

    30.  Hainwright PJ, Mioton LM, Thomassee MS, et al. Risk profiles and outcomes of total laparoscopic hysterectomy compared with laparoscopically assisted vaginal hysterectomy. Obstet Gynecol. 2013;121(4):781–787.

    31.  Manchanda R, Abdelraheim A, Johnson M, et al. Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG. 2011;118:814–824.

    32.  Lamb JD, Garcia RL, Goff BA, et al. Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. Am J Obstet Gynecol. 2006;194:1702–1709.

    33.  Viscus D, Shaw PA, Finch A, et al. Risk factors for non-invasive lesions in the Fallopian tube in BRCA mutation carriers. Gynecol Oncol. 2010; 118:295–298.

    34.  Powell CB, Swisher EM, Cass I, et al. Long term follow up of BRCA1 and BRCA2 mutation carriers with unsuspected neoplasia identified at risk-reducing salpingo-oophorectomy. Gynecol Oncol. 2013;129(2): 364–371.

    35.  Powell CB. Risk reducing salpingo-oophorectomy for BRCA mutation carriers: Twenty years later. Gynecol Oncol. 2014;133 (2): 261–262.

    36.  National Comprehensive Cancer Network. NCCN clinical practice guidelines. Oncology: Genetic/familial High-risk Assessment: Breast and Ovarian. Version1. 2010. Fort Washington, PA.

    37.  Chapman J, Powell CB, McLennan J, et al. Surveillance of survivors: Follow-up after risk-reducing salpingo-oophorectomy in BRCA1/2 mutation carriers. Gynecol Oncol. 2011;122:339–343.

    38.  Greene MH, Mai PL, Schwartz PE. Does bilateral salpingectomy with ovarian retention warrant consideration as a temporary bridge to risk-reducing bilateral oophorectomy in BRCA1/2 mutation carriers? Am J Obstet Gynecol. 2011;204:19.e1–6.

    39.  Society of Gynecologic Oncology. SGO Clinical Practice Statement: Salpingectomy for ovarian cancer prevention. https://www.sgo.org/clinical-practice/guidelines/sgo-clinical-practice-s.... Accessed February 18, 2015.

    40.  Morelli M, Venturella R, Mocciaro R, et al. Prophylactic salpingectomy in premenopausal low-risk women for ovarian cancer: primum non nocere. Gynecol Oncol. 2013;129(3):448–451.

    41.  Kwon JS, Tinker A, Pansegrau G, et al. Prophylactic salpingectomy and delayed oophorectomy as an alternative for BRCA mutation carriers. Obstet Gynecol. 2013;121:14–24.

    42.  Gilks CB, Miller D. Opportunistic salpingectomy for women at low risk for development of ovarian cancer: the time has come. Gynecol Oncol. 2013;129:443–444.

    Ilana Cass, MD
    Dr. Cass is an Assistant Professor of Obstetrics and Gynecology, UCLA/Cedars-Sinai Medical Center, Los Angeles, Calif.


    You must be signed in to leave a comment. Registering is fast and free!

    All comments must follow the ModernMedicine Network community rules and terms of use, and will be moderated. ModernMedicine reserves the right to use the comments we receive, in whole or in part,in any medium. See also the Terms of Use, Privacy Policy and Community FAQ.

    • No comments available


    Latest Tweets Follow